New Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals’ PS-Targeting Antibodies in a Preclinical Melanoma Model -- Promising Results of MSK Study Evaluating Combinations of PS-Targeting Treatment, Anti-PD-1 and Radiation in Mouse B16 Melanoma Model Presented at SITC 2016 -- -- New Data from Second Study...

New XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual Meeting Preclinical Data from XOMA’s Novel Anti-IL-2 Immuno-oncology Monoclonal Antibodies Program to be Presented at SITCAdvancing Unique Functional Antibody Antagonists Targeting the Parathyroid Hormone...

New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab’s Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma - Bavituximab in Combination with Anti-PD-1 in Breast Cancer Studies Showed a Statistically Significant Improvement in Overall Survival as Compared to Subjects Receiving Anti-PD-1 Therapy Alone - -...

OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting NATIONAL HARBOR, Md. and REDWOOD CITY, Calif., Nov. 07, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and...

OncoMed to Present Preclinical Data for the Combination of anti-DLL4/VEGF Bispecific plus anti-PD1 at the Society of Immunotherapy for Cancer Meeting REDWOOD CITY, Calif., Nov. 04, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced that new data comparing the anti-tumor immune response of its anti-DLL4/VEGF bispecific...